BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1073 related articles for article (PubMed ID: 31563690)

  • 1. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
    Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
    Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
    Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
    Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 7. Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma.
    Wang Z; Wang YS; Chang ZM; Li L; Zhang Y; Lu MM; Zheng X; Li M; Shao D; Li J; Chen L; Dong WF
    Chem Biol Drug Des; 2017 Mar; 89(3):464-469. PubMed ID: 27618577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
    Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
    Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy.
    Fang J; Zhang S; Xue X; Zhu X; Song S; Wang B; Jiang L; Qin M; Liang H; Gao L
    Int J Nanomedicine; 2018; 13():5113-5126. PubMed ID: 30233175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy.
    Jiang B; Zhang R; Zhang J; Hou Y; Chen X; Zhou M; Tian X; Hao C; Fan K; Yan X
    Theranostics; 2019; 9(8):2167-2182. PubMed ID: 31149036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
    Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
    Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
    Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment.
    Chen Y; Li H; Deng Y; Sun H; Ke X; Ci T
    Acta Biomater; 2017 Mar; 51():374-392. PubMed ID: 28088668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma.
    Wang Y; Yi Y; Yao J; Wan H; Yu M; Ge L; Zeng X; Wu M; Mei L
    Acta Biomater; 2022 Nov; 153():518-528. PubMed ID: 36152910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.